Global Registry study
"1. Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
2. Has at least one HbA1C (Hemoglobin a1c) measurement obtained within the three (3) months prior to the start date of first Dexcom CGM System use in the study (blinded or unblinded, whichever first). For participants with prior CGM experience (CGM non-naive), this HbA1c measurement must also be at least three (3) months after the end of any CGM usewithin three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use
3. Participant is willing and able to use Dexcom CGM System according to approved product labeling
4. Participant is willing and able to complete applicable patient reported outcome assessments/ surveys
"1. Is contraindicated for a Dexcom CGM System per approved commercial labeling
2. In the Investigator's opinion, the participant is not considered to be a suitable candidate
3. Currently participating in another study and receiving and intervention study"
The study intends to prioritize enrollment of participants living with Type 2 Diabetes (T2D): Intensive Insulin Therapy (IIT), Basal Insulin, and Non-Insulin Taking (NIT), participants.
Case-only
Prospective
Dexcom CGM (Continuous Glucose Monitor)
DeviceUse Dexcom CGM according to approved commercial use. Evaluate HbA1c over time.
Evaluations
Evaluate outcomes of CGM use for each diabetes type within a given country
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
